<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36226380</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>02</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-9071</ISSN><JournalIssue CitedMedium="Internet"><Volume>95</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of medical virology</Title><ISOAbbreviation>J Med Virol</ISOAbbreviation></Journal><ArticleTitle>Persistence of neutrophil extracellular traps and anticardiolipin auto-antibodies in post-acute&#xa0;phase COVID-19 patients.</ArticleTitle><Pagination><StartPage>e28209</StartPage><MedlinePgn>e28209</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e28209</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/jmv.28209</ELocationID><Abstract><AbstractText>In the early phase of the pandemic, we were among the first to postulate that neutrophil extracellular traps (NETs) play a key role in COVID-19 pathogenesis. This exploratory prospective study based on 279 individuals showed that plasma levels of neutrophil elastase, myeloperoxidase and circulating DNA of nuclear and mitochondrial origins in nonsevere (NS), severe (S) and postacute phase (PAP) COVID-19 patients were statistically different as compared to the levels in healthy individuals, and revealed the high diagnostic power of these NETs markers in respect to the disease severity. The diagnostic power of NE, MPO, and cir-nDNA as determined by the Area Under Receiver Operating Curves (AUROC) was 0.95, 097, and 0.64; 0.99, 1.0, and 0.82; and 0.94, 1.0, and 0.93, in NS, S, and PAP patient subgroups, respectively. In addition, a significant fraction of NS, S as well as of PAP patients exhibited aCL IgM/IgG and anti-B2GP IgM/IgG positivity. We first demonstrate persistence of these NETs markers in PAP patients and consequently of sustained innate immune response imbalance, and a prolonged low-level pro-thrombotic potential activity highlighting the need to monitor these markers in all COVID-19 PAP individuals, to investigate postacute COVID-19 pathogenesis following intensive care, and to better identify which medical resources will ensure complete patient recovery.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pisareva</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0617-6889</Identifier><AffiliationInfo><Affiliation>IRCM, Institut de Recherche en Canc&#xe9;rologie de Montpellier, INSERM U1194, Institut R&#xe9;gional du Cancer de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badiou</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Hormonology, INSERM, CNRS, University Hospital Center of Montpellier, University of Montpellier, PhyMedExp, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mihalovi&#x10d;ov&#xe1;</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>IRCM, Institut de Recherche en Canc&#xe9;rologie de Montpellier, INSERM U1194, Institut R&#xe9;gional du Cancer de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Faculty of Medicine, Institute of Molecular Biomedicine, Comenius University, Bratislava, Slovakia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirandola</LastName><ForeName>Alexia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCM, Institut de Recherche en Canc&#xe9;rologie de Montpellier, INSERM U1194, Institut R&#xe9;gional du Cancer de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Brice</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>IRCM, Institut de Recherche en Canc&#xe9;rologie de Montpellier, INSERM U1194, Institut R&#xe9;gional du Cancer de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kudriavtsev</LastName><ForeName>Andrei</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCM, Institut de Recherche en Canc&#xe9;rologie de Montpellier, INSERM U1194, Institut R&#xe9;gional du Cancer de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, INSERM U1046, CNRS, Montpellier University Hospital, Montpellier, PhyMedExp, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roubille</LastName><ForeName>Camille</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, INSERM U1046, CNRS, Montpellier University Hospital, Montpellier, PhyMedExp, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fesler</LastName><ForeName>Pierre</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, INSERM U1046, CNRS, Montpellier University Hospital, Montpellier, PhyMedExp, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klouche</LastName><ForeName>Kada</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine Department, INSERM, CNRS, Lapeyronie Hospital, University Hospital of Montpellier, France, and PhyMedExp, University of Montpellier, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cristol</LastName><ForeName>Jean-Paul</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Hormonology, INSERM, CNRS, University Hospital Center of Montpellier, University of Montpellier, PhyMedExp, Montpellier, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thierry</LastName><ForeName>Alain R</ForeName><Initials>AR</Initials><Identifier Source="ORCID">0000-0002-4632-5404</Identifier><AffiliationInfo><Affiliation>IRCM, Institut de Recherche en Canc&#xe9;rologie de Montpellier, INSERM U1194, Institut R&#xe9;gional du Cancer de Montpellier, Universit&#xe9; de Montpellier, Montpellier, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Montpellier Cancer Institute (ICM), Montpellier, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Virol</MedlineTA><NlmUniqueID>7705876</NlmUniqueID><ISSNLinking>0146-6615</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017153">Antibodies, Anticardiolipin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007075">Immunoglobulin M</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065206" MajorTopicYN="Y">Extracellular Traps</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017153" MajorTopicYN="N">Antibodies, Anticardiolipin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007075" MajorTopicYN="N">Immunoglobulin M</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anti-cardiolipin</Keyword><Keyword MajorTopicYN="N">circulating DNA</Keyword><Keyword MajorTopicYN="N">diagnosis</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">neutrophil extracellular traps</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>13</Day><Hour>3</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36226380</ArticleId><ArticleId IdType="pmc">PMC9874393</ArticleId><ArticleId IdType="doi">10.1002/jmv.28209</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Nalbandian A, Sehgal K, Gupta A, et al. Post&#x2010;acute COVID&#x2010;19 syndrome. Nat Med. 2021;27(4):601&#x2010;615. 10.1038/s41591-021-01283-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01283-z</ArticleId><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Narayan RK, Prasoon P, et al. COVID&#x2010;19 mechanisms in the human body&#x2014;what we know so far. Front Immunol. 2021;12:693938. 10.3389/fimmu.2021.693938</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.693938</ArticleId><ArticleId IdType="pmc">PMC8592035</ArticleId><ArticleId IdType="pubmed">34790191</ArticleId></ArticleIdList></Reference><Reference><Citation>Thierry AR, Roch B. Neutrophil extracellular traps and by&#x2010;products play a key role in COVID&#x2010;19: pathogenesis, risk factors, and therapy. JCM. 2020;9(9):2942. 10.3390/jcm9092942</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9092942</ArticleId><ArticleId IdType="pmc">PMC7565044</ArticleId><ArticleId IdType="pubmed">32933031</ArticleId></ArticleIdList></Reference><Reference><Citation>Barnes BJ, Adrover JM, Baxter&#x2010;Stoltzfus A, et al. Targeting potential drivers of COVID&#x2010;19: neutrophil extracellular traps. J Exp Med. 2020;217(6):e20200652. 10.1084/jem.20200652</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20200652</ArticleId><ArticleId IdType="pmc">PMC7161085</ArticleId><ArticleId IdType="pubmed">32302401</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazeldine J, Lord JM. Neutrophils and COVID&#x2010;19: active participants and rational therapeutic targets. Front Immunol. 2021;12:680134. 10.3389/fimmu.2021.680134</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.680134</ArticleId><ArticleId IdType="pmc">PMC8206563</ArticleId><ArticleId IdType="pubmed">34149717</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol. 2022;44:347&#x2010;362. 10.1007/s00281-022-00916-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-022-00916-w</ArticleId><ArticleId IdType="pmc">PMC8816310</ArticleId><ArticleId IdType="pubmed">35122116</ArticleId></ArticleIdList></Reference><Reference><Citation>Thierry AR. Anti&#x2010;protease treatments targeting plasmin(ogen) and neutrophil elastase may be beneficial in fighting COVID&#x2010;19. Physiol Rev. 2020;100(4):1597&#x2010;1598. 10.1152/physrev.00019.2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physrev.00019.2020</ArticleId><ArticleId IdType="pmc">PMC7365835</ArticleId><ArticleId IdType="pubmed">32639219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID&#x2010;19. JCI Insight. Published online April 24, 2020;5:e138999. 10.1172/jci.insight.138999</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.138999</ArticleId><ArticleId IdType="pmc">PMC7308057</ArticleId><ArticleId IdType="pubmed">32329756</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID&#x2010;19 acute respiratory distress syndrome. Blood. 2020;136(10):1169&#x2010;1179. 10.1182/blood.2020007008</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng H, Havervall S, Rosell A, et al. Circulating markers of neutrophil extracellular traps are of prognostic value in patients with COVID&#x2010;19. ATVB. 2021;41(2):988&#x2010;994. 10.1161/ATVBAHA.120.315267</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315267</ArticleId><ArticleId IdType="pmc">PMC7837697</ArticleId><ArticleId IdType="pubmed">33267662</ArticleId></ArticleIdList></Reference><Reference><Citation>Pastor B, Abraham JD, Pisareva E, et al. Association of neutrophil extracellular traps with the production of circulating DNA in patients with colorectal cancer. iScience. 2022;25(2):103826. 10.1016/j.isci.2022.103826</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2022.103826</ArticleId><ArticleId IdType="pmc">PMC8844218</ArticleId><ArticleId IdType="pubmed">35198886</ArticleId></ArticleIdList></Reference><Reference><Citation>Al&#x2010;Aly Z, Xie Y, Bowe B. High&#x2010;dimensional characterization of post&#x2010;acute sequelae of COVID&#x2010;19. Nature. 2021;594(7862):259&#x2010;264. 10.1038/s41586-021-03553-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03553-9</ArticleId><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanos R, Tosato G, Otandault A, et al. Machine learning&#x2010;assisted evaluation of circulating DNA quantitative analysis for cancer screening. Adv Sci. 2020;7(18):2000486. 10.1002/advs.202000486</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202000486</ArticleId><ArticleId IdType="pmc">PMC7509651</ArticleId><ArticleId IdType="pubmed">32999827</ArticleId></ArticleIdList></Reference><Reference><Citation>Medini H, Zirman A, Mishmar D. Immune system cells from COVID&#x2010;19 patients display compromised mitochondrial&#x2010;nuclear expression co&#x2010;regulation and rewiring toward glycolysis. iScience. 2021;24(12):103471. 10.1016/j.isci.2021.103471</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2021.103471</ArticleId><ArticleId IdType="pmc">PMC8599136</ArticleId><ArticleId IdType="pubmed">34812416</ArticleId></ArticleIdList></Reference><Reference><Citation>Cambier S, Metzemaekers M, de Carvalho AC, et al. Atypical response to bacterial coinfection and persistent neutrophilic bronchoalveolar inflammation distinguish critical COVID&#x2010;19 from influenza. JCI Insight. 2022;7(1):e155055. 10.1172/jci.insight.155055</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.155055</ArticleId><ArticleId IdType="pmc">PMC8765057</ArticleId><ArticleId IdType="pubmed">34793331</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuchs TA, Kremer Hovinga JA, Schatzberg D, Wagner DD, L&#xe4;mmle B. Circulating DNA and myeloperoxidase indicate disease activity in patients with thrombotic microangiopathies. Blood. 2012;120(6):1157&#x2010;1164. 10.1182/blood-2012-02-412197</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-02-412197</ArticleId><ArticleId IdType="pmc">PMC3418712</ArticleId><ArticleId IdType="pubmed">22611154</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinnare N, Hook JS, Patel PA, Monson NL, Moreland JG. Neutrophil extracellular trap formation potential correlates with lung disease severity in COVID&#x2010;19 patients. Inflammation. 2021;45:800&#x2010;811. 10.1007/s10753-021-01585-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10753-021-01585-x</ArticleId><ArticleId IdType="pmc">PMC8557104</ArticleId><ArticleId IdType="pubmed">34718927</ArticleId></ArticleIdList></Reference><Reference><Citation>Bivona G, Agnello L, Ciaccio M. Biomarkers for prognosis and treatment response in COVID&#x2010;19 patients. Ann Lab Med. 2021;41(6):540&#x2010;548. 10.3343/alm.2021.41.6.540</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2021.41.6.540</ArticleId><ArticleId IdType="pmc">PMC8203437</ArticleId><ArticleId IdType="pubmed">34108281</ArticleId></ArticleIdList></Reference><Reference><Citation>Asherson RA. Antiphospholipid antibodies and infections. Ann Rheum Dis. 2003;62(5):388&#x2010;393. 10.1136/ard.62.5.388</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.5.388</ArticleId><ArticleId IdType="pmc">PMC1754545</ArticleId><ArticleId IdType="pubmed">12695147</ArticleId></ArticleIdList></Reference><Reference><Citation>Harzallah I, Debliquis A, Dr&#xe9;nou B. Lupus anticoagulant is frequent in patients with Covid&#x2010;19. J Thromb Haemost. 2020;18(8):2064&#x2010;2065. 10.1111/jth.14867</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14867</ArticleId><ArticleId IdType="pmc">PMC7264773</ArticleId><ArticleId IdType="pubmed">32324958</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID&#x2010;19. Sci Transl Med. 2020;12(570):eabd3876. 10.1126/scitranslmed.abd3876</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollerbach A, M&#xfc;ller&#x2010;Calleja N, Pedrosa D, et al. Pathogenic lipid&#x2010;binding antiphospholipid antibodies are associated with severity of COVID&#x2010;19. J Thromb Haemost. 2021;19(9):2335&#x2010;2347. 10.1111/jth.15455</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15455</ArticleId><ArticleId IdType="pmc">PMC8420426</ArticleId><ArticleId IdType="pubmed">34242469</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi H, Zuo Y, Navaz S, et al. Endothelial cell&#x2010;activating antibodies in COVID&#x2010;19. Arthritis Rheumatol. 2022;74(7):1132&#x2010; 1138. 10.1002/art.42094</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.42094</ArticleId><ArticleId IdType="pmc">PMC9082472</ArticleId><ArticleId IdType="pubmed">35174669</ArticleId></ArticleIdList></Reference><Reference><Citation>Tambralli A, Gockman K, Knight JS. NETs in APS: current knowledge and future perspectives. Curr Rheumatol Rep. 2020;22(10):67. 10.1007/s11926-020-00936-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-020-00936-1</ArticleId><ArticleId IdType="pubmed">32845378</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahnach M, Zbiri S, Nejjari S, Ousti F, Elkettani C. C&#x2010;reactive protein as an early predictor of COVID&#x2010;19 severity. J Med Biochem. 2020;39(4):500&#x2010;507. 10.5937/jomb0-27554</Citation><ArticleIdList><ArticleId IdType="doi">10.5937/jomb0-27554</ArticleId><ArticleId IdType="pmc">PMC7710381</ArticleId><ArticleId IdType="pubmed">33312067</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Zhou W, Yan X, et al. Prognostic value of C&#x2010;reactive protein in patients with coronavirus 2019. Clin Infect Dis. 2020;71(16):2174&#x2010;2179. 10.1093/cid/ciaa641</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa641</ArticleId><ArticleId IdType="pmc">PMC7314209</ArticleId><ArticleId IdType="pubmed">32445579</ArticleId></ArticleIdList></Reference><Reference><Citation>Montesarchio V, Parrela R, Iommelli C, et al. Outcomes and biomarker analyses among patients with COVID&#x2010;19 treated with interleukin 6 (IL&#x2010;6) receptor antagonist sarilumab at a single institution in Italy. J Immunother Cancer. 2020;8(2):e001089. 10.1136/jitc-2020-001089</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jitc-2020-001089</ArticleId><ArticleId IdType="pmc">PMC7418768</ArticleId><ArticleId IdType="pubmed">32784217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post&#x2010;COVID&#x2010;19 symptom burden: what is long&#x2010;COVID and how should we manage it. Lung. 2021;199(2):113&#x2010;119. 10.1007/s00408-021-00423-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00408-021-00423-z</ArticleId><ArticleId IdType="pmc">PMC7875681</ArticleId><ArticleId IdType="pubmed">33569660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S, Barnett J, Brill SE, et al. &#x2018;Long&#x2010;COVID&#x2019;: a cross&#x2010;sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID&#x2010;19. Thorax. 2021;76(4):396&#x2010;398. 10.1136/thoraxjnl-2020-215818</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Calcaianu G, Degoul S, Michau B, et al. Mid&#x2010;term pulmonary sequelae after hospitalisation for COVID&#x2010;19: the French SISCOVID cohort. Respir Med Res. 2022;82:100933. 10.1016/j.resmer.2022.100933</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resmer.2022.100933</ArticleId><ArticleId IdType="pmc">PMC9192129</ArticleId><ArticleId IdType="pubmed">35905553</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>